Schellingerhout Laboratory

Co-Principal Investigator. Predicting Radiation-Induced Cord Myelopathy Using a Molecular Imaging Readout of Retrograde Axonal Transport to Predict Myelopathy, MDACC Center for Radiation Oncology Research Seed Funding Program, 01/01/2016 – 12/31/2016. The purpose of this project is to investigate the ability of molecular imaging, used as a readout of retrograde axonal transport, to predict myelopathic radiation injury to the spinal cord.

Principal Investigator. A New Treatment for Brain Tumors: Targeting Tumor Metabolism with Glucose-based Therapeutic Agents and Monitoring Treatment Response with Hyperpolarized MR-Spectroscopy, Rose Foundation, 11/01/2015–10/31/2016. The goal of this project is to use Hyperpolarized Pyruvate imaging to assess the metabolic effects of anti-glycolytic therapies in glioma.

Principal Investigator (10%). Hemorrhagic versus Calcific Brain Lesion Study ($581,037), 8/01/2015–5/01/2018, CABI GE Healthcare Award. The purpose of this project is to use Dual Energy CT and Phase Sensitive MR in a clinical trial to characterize brain lesions, and allow high-risk hemorrhagic lesions to be better discriminated from low-risk calcific lesions.

Principal Investigator (0%). Predicting Radiation-Induced Cord Myelopathy Using a Molecular Imaging Readout of Retrograde Axonal Transport to Predict Myelopathy. Total funding: $60,000, 9/1/2015–8/31/2016 (6-month extension possible), Center for Radiation Oncology Research Seed Funding Program.

Principal Investigator. Radiologic-Pathologic Correlation on Stereotactic Biopsies in Glioma Patients, MD Anderson Cancer Center Institutional Research Grant, 2/1/2015–1/31/2017. The purpose of this project is to fund pathologic analysis of samples harvested in the Stereotactic RadPath trial.

Collaborator (0%). Development of Unconventional MRI Approaches to Imaging Cancer Immunotherapy, $200,000 over 2 years. Awarded Aug 17, 2015, CABI MI2.

Principal Investigator (0%). Targeting the Glycolytic Pathway in the Therapy of Glioma, with Imaging Feedback of Efficacy by Means of Hyperpolarized MR Spectroscopy, Rose Foundation, 7/2014.

Co-Investigator, Preserving Genital Nerve Function in Prostate Cancer: Imaging with a Molecular Imaging Agent, MD Anderson Minimally Invasive and New Technology in Oncologic Surgery, 2/2014–4/30/2015.

Principal Investigator, (0% support). Molecular Neurographic Imaging to Preserve Genital Nerve Function in Prostate Cancer, MD Anderson-Washington University p50 Molecular Imaging Center Pilot Project Program, 2/1/2014–12/31/2014.

Co-Investigator, Reducing the Impact of Chemotherapy-Induced Neuropathies on Cancer Patients: Understanding the Molecular Mechanisms of Disease, Mike Hogg Fund, 10/2013–1/2014.

Co-Investigator, (0% support). Characterization of Calcium and Iron Solutions using Gemstone Spectral Imaging CT to distinguish between Hemorrhagic and Calcific Lesions, Center for Advanced Biomedical Imaging, 7/2012–7/2014

Principal Investigator (13%). Molecular Imaging of Retrograde Nerve Transport, 5 R01 NS070742 02, NIH/NINDS, 3/1/2011–2/28/2016.

Principal Investigator, (2% effort). Molecular Imaging of Treatments for Oxaliplatin Neurotoxicity, 05-05-04032, The Mike Hogg Fund, 1/1/2011–6/30/2012.

Principal Investigator, (0% effort funded). Bridge Funding: Molecular Imaging of Retrograde Nerve Transport, The University of Texas MD Anderson Cancer Center, 7/2010–1/2012.